Cti Biopharma Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CTI BIOPHARMA CORP, and when can generic versions of CTI BIOPHARMA CORP drugs launch?
CTI BIOPHARMA CORP has one approved drug.
There are three US patents protecting CTI BIOPHARMA CORP drugs.
There are sixty-six patent family members on CTI BIOPHARMA CORP drugs in twenty-seven countries.
Summary for Cti Biopharma Corp
International Patents: | 66 |
US Patents: | 3 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Cti Biopharma Corp
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 8,980,873 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 8,153,632 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cti Biopharma Corp Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5225856 | ⤷ Subscribe |
South Korea | 20140037256 | ⤷ Subscribe |
South Korea | 20140117679 | ⤷ Subscribe |
Hong Kong | 1124040 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.